ArticleMikrochimica acta2026
Label-free electrochemiluminescence aptasensing platform: Au-LDH-C
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Carcinoembryonic antigen (CEA), a crucial non-specific tumor biomarker, exhibited a normal serum level of 2.5-5.0 ng/mL in healthy individuals. Elevations beyond this range signify increased tumor risk, underscoring the critical need for early biomarker detection. This study developed an inhibited electrochemiluminescence (ECL) aptasensor for ultrasensitive CEA detection, leveraging an Au-LDH-C3N4 composite as both the luminophore and sensing platform. The synthesis of Au-LDH- C3N4 involved the initial preparation of C3N4 by thermal pyrolysis of melamine, the subsequent in-situ growth of cobalt-iron layered double hydroxide (LDH) to form LDH-C3N4, and the final in-situ deposition of Au NPs. The resulting Au-LDH-C3N4 nanocomposite integrated the advantages of its components: the LDH-C3N4 heterojunction enhanced ECL stability and charge separation, oxygen vacancies promoted the generation of sulfate radicals (SO4·⁻), and Au NPs improved electron transfer. Leveraging these synergistic effects, a label-free ECL sensing platform was constructed. The design of the nucleic acid probes using a complementary single-stranded DNA as a stable anchor and a specific aptamer for target recognition-ensured effective surface immobilization and high recognition specificity. The fabricated aptasensor achieved remarkable performance for CEA detection, featuring an extensive linear range (0.001 to 20 ng/mL) and an exceptionally low detection limit (0.3 pg/mL based on 3σ/S). In addition, the prepared aptasensor was successfully applied to serum analysis resulting in satisfactory results. This work presented the development of Au-LDH-C3N4-based ECL aptasensors and established an effective strategy for early detection of CEA.
Indexed as
Identifiers
41489643What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.